Results 41 to 50 of about 29,799 (243)

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Comparative efficacy of inhalers in mild-to-moderate asthma: systematic review and network meta-analysis

Scientific Reports, 2022
The comparative effectiveness of different inhaler therapies in mild-to-moderate asthma remains unclear. To assess this, we performed a systematic review and network meta-analysis of randomized controlled trials on the use of inhalers for mild-to ...
Hyung Jun Park, Jin-Young Huh, Ji Sung Lee, Jae Seung Lee, Yeon-Mok Oh, Sei Won Lee   +5 more
doaj   +1 more source

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Advanced Science, EarlyView.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon   +19 more
wiley   +1 more source

Long-acting β2-agonists in asthma: enantioselective safety studies are needed

, 2018
Long-acting β2-agonists (LABAs) such as formoterol and salmeterol are used for prolonged bronchodilatation in asthma, usually in combination with inhaled corticosteroids (ICSs). Unexplained paradoxical asthma exacerbations and deaths have been associated
Glenn Jacobson (14740078), Eugene Walters (14752090), Hostrup, M (15639605), Farber, MO (15673400), Calzetta, L (15673397), Page, CP (15673403), Wood-Baker, R (15478649), Raidal, S (15660974)   +7 more
core   +2 more sources

Astrocytic Phenotypic Switching in Posterior Piriform Cortex Orchestrates Bone Cancer Pain–Depression Comorbidity via Purinergic–Noradrenergic Signaling

Advanced Science, EarlyView.
Bone cancer pain and depression share a common origin: astrocytic A2‐to‐A1 transition in the posterior piriform cortex. This phenotypic shift disrupts the ATP–adenosine–A2AR–norepinephrine axis, simultaneously driving nociceptive and affective dysfunction.
Jiang‐Ping Liu, Jun‐Han Zhang, Zhi‐Xuan Tan, Wei‐Bing Yan, Ya‐Ru Yuan, Yao Liu, Bing‐Di Wei, Meng‐Qi Ding, Zhuo‐Min Fu, Ying Liu, An‐Qi Wang, Lin Ma, Yong‐Hong Li, Er‐Qing Chai, Chao‐Jun Wei   +14 more
wiley   +1 more source

Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra long-acting β2-adrenoceptor agonist (uLABA), with formoterol in patients with asthma.

, 2013
Pharmacologically mediated bronchodilation is important in the management of asthma, and is primarily achieved with β2-agonists. Novel compounds should preferably have a longer duration of action and a better systemic side effect profile than established
Lötvall, Jan, Rosenborg, Johan, Jan Lötvall, Johan Rosenborg, Leif Bjermer, Thomas Bengtsson, Bengtsson, Thomas, Bjermer, Leif   +7 more
core   +2 more sources

Patient response and remission in respiratory disease: Special focus on severe asthma and chronic obstructive pulmonary disease

Journal of International Medical Research
Over the past decades, monoclonal antibodies have been playing a pivotal role in the treatment of chronic inflammatory airway diseases. Currently, ample data are available on the efficacy and safety of biologics in asthma from randomized controlled ...
Stefania Colantuono, Francesco Menzella, Pier-Valerio Mari, Francesco Macagno, Francesco Lombardi, Ilaria Baglivo, Cristiano Caruso   +6 more
doaj   +1 more source

Effect of Transdermal Tulobuterol Added to Inhaled Corticosteroids in Asthma Patients

Allergology International, 2005
Background: Tulobuterol tape is the first long-acting transdermal preparation of a p2-agonist designed to release tulobuterol in an optimal fashion over a 24-hour period.
Gen Tamura, Yasuyuki Sano, Kazuto Hirata, Shinichi Ishioka, Mitsuyoshi Nakashima, Terumasa Miyamoto   +5 more
doaj   +1 more source

Lung function response to 12-week treatment with combined inhalation of long-acting β2 agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease

, 2018
Recent reports suggest that β2-adrenergic receptor (ADRB2) genotypes are associated with therapeutic responses to β2 agonists in asthmatics. However, few studies have investigated therapeutic responses to β2 agonists in chronic obstructive pulmonary ...
이진화
core   +1 more source

Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma [PDF]

, 2010
Background Formoterol is a long-acting beta(2)-agonist but because it has a fast onset of action it can also be used as a relief medication. Objectives To asses the efficacy and safety of formoterol as reliever therapy in comparison to short-acting ...
Christopher J Cates, Emma J Welsh, Welsh, EJ, Cates, CJ   +3 more
core   +1 more source